Clinical Trials Browser

Interventional × magrolimab × Lymphoid × Clear all

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1/2 Terminated

8 enrolled 8 charts

Mycosis Fungoides, Sezary Syndrome

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase 1 Completed

11 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05929716 2023-11-13

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Withdrawn

Lymphoma, B-Cell

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse